BTK inhibitor Archives -

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although

Sanofi pauses enrolment in ex-US tolebrutinib trials

https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/

One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after

Liver injuries prompt clinical hold on Sanofi BTK drug

https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/

Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese

Biogen builds MS pipeline via $125m deal with China’s InnoCare

https://pharmaphorum.com/news/biogen-builds-ms-pipeline-via-125m-deal-with-chinas-innocare/

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment

AZ says Calquence is a safer drug than Imbruvica

https://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

https://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/

AbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

https://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/

BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s

China’s BeiGene delays US filing for rival to Imbruvica

https://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/

BTK inhibitor